Buy Lincoln Pharma; target of Rs 322: Firstcall

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Firstcall's research report on Lincoln PharmaLincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India. Lincoln Pharmaceuticals Limited manufactures, markets, and exports pharmaceutical products in India and internationally. The company’s product categories include antimalarial, antibiotics, anti-bactarials, analgesics, anti-inflammatory, anti-pyretics, anti-hypertensives, anti-fungal, antacids, anti-ulcers, anthelmintics, anti-cold, anti-allergic, anti-asthmatics, anti-emetics, gastrointestinal-agents, anti-diarrhoeals, anti-spasmodics, and pro- biotics, as well as cardiac and diuretic products. It also provides creams, ointments, anti-infectives, vitamins, minerals, and iron-preparations. In addition, the company trades finished goods, chemicals products, and bulk drugs. The company’s new world-class, totally computerized plant is located in Ahmadabad near Khatraj with all amenities to manufacture and export pharmaceuticals. The pharma manufacturing unit produces tablets, capsules, injections, liquid and dry syrups (dry powder). The new factory has fully computerized system for production with online controls and inventory. It also has highly qualified and trained staff for production management. Right from inception, Lincoln puts a major thrust on developing innovative and technology based products aiming at optimizing the use of drugs for better therapeutic purposes. The R & D center is equipped with sophisticated instruments and equipments for in-house physical, chemical and microbiological analysis of all products.Price to Book Value of the stock is expected to be at 3.56 x and 3.02 x for FY16E and FY17E respectively. Hence, we recommend ‘BUY’ in this particular scrip with a target price of Rs. 322.00 for Medium to Long term investment.For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More